As the vibrant festival of Holi approaches in 2025, investors are turning their attention to promising stock picks. Bajaj Broking has identified two lucrative opportunities: Piramal Pharma Limited and PTC India Limited. With projected upsides exceeding 15%, these stocks could brighten your portfolio this festive season.
PTC India: A Strong Buy Recommendation
Bajaj Broking has set a buying range for PTC India between ₹150 and ₹157, with an ambitious target price of ₹178. This target suggests a potential upside of approximately 16% within a 12-month timeframe.
- The recent breakout in PTC India’s share price, surpassing the previous 3-month range of ₹130 to ₹154, indicates a positive trend.
- Analysts believe this movement signals a fresh entry point for investors looking to capitalize on the stock’s upward trajectory.
Bajaj Broking anticipates that PTC India will reach its target of ₹178 in the upcoming quarters, driven by the confluence of the breakout implications and a 50% retracement from its previous decline.
Piramal Pharma: Promising Growth Ahead
For Piramal Pharma, Bajaj Broking recommends a buying range of ₹193 to ₹203. The projected target price stands at ₹229, also reflecting a potential upside of around 16% within a 12-month horizon.
- Following a recent correction, Piramal Pharma’s stock is establishing a base around its long-term 52-week EMA, which presents a favorable risk-reward scenario for new investors.
- The brokerage expects the stock to approach ₹229, marking a significant retracement area and trendline resistance based on historical highs.
Key Catalysts for Piramal Pharma
Bajaj Broking highlights several factors that could influence Piramal Pharma’s performance:
- Improvement in biotech funding in the USA is anticipated, although growth in R&D spending may be slow, potentially impacting CDMO opportunities at the industry level.
- A surge in demand for the company’s inhalation anesthesia (IA) products in the USA market is encouraging.
- Piramal Pharma is also expanding its production capacities at facilities in Dahej and Digwal, which is expected to enhance its CHG business in various global markets.
In summary, as Holi 2025 approaches, both PTC India and Piramal Pharma present compelling investment opportunities. With their projected gains and strategic market positioning, these stocks could be the colorful additions your investment portfolio needs this festive season.
